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Encapsulating summary Our data suggest that a basophil level above 0.18% of the 30 
PBMC population during an acute respiratory exacerbation is associated with an 31 
increased risk for future exacerbations in children with asthma and/or wheeze. 32 
 33 
  34 
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To the Editor 35 
During early childhood, respiratory infections may result in wheezing episodes, which 36 
together with atopy commonly precede asthma development (1). A subset of 37 
wheezing children experience frequent exacerbations and are overrepresented among 38 
respiratory hospitalisations, and are estimated to be responsible for ~80% of health 39 
care costs associated with asthma and related diseases (2). Patients with recurrent 40 
exacerbations exist throughout the full range of the asthma exacerbation severity 41 
spectra but are at high risk of irreversible airflow limitations and loss of 42 
responsiveness to available therapeutics (3). Hence, early identification of these 43 
children is crucial for tailored treatment regimens and may also help to better 44 
understand the mechanisms of the development of recurrent exacerbations. There are 45 
currently no appropriate biomarkers that reliably identify children at risk of recurrent 46 
exacerbations. 47 
 48 
Asthma-associated airway inflammation results in the recruitment of immune cells 49 
from the circulation and promotes an altered immune cell output from the bone 50 
marrow. Thus, the circulating peripheral blood mononuclear cell (PBMC) population 51 
reflects disease activity and phenotype (4, 5). Since these cells are en route to 52 
respiratory tissues and are more easily accessible in children than lung tissue, we have 53 
focused on the PBMC population, as a source of immune cells, to identify cellular 54 
response profiles associated with recurrent exacerbations. The cellular PBMC profile 55 
was characterised during an exacerbation using multi-parameter flow cytometry, to 56 
identify how proportions and activation status of dendritic cells, basophils, B cells, 57 
monocytes and T cells within the PBMC preparation (Fig E1A-B), differ between 58 
patients with few versus multiple previous exacerbations. 59 
 60 
To define an exacerbation-prone phenotype, we divided the patients into two groups 61 
comprising those with high versus low exacerbation recurrence. By using a cut-off of 62 
4 prevous wheezing or acute asthma exacerbations, we separated approximately the 63 
top quarter of recurrent patients (Fig 1A-B). Between the two patient groups, there 64 
was no difference in sex, age at recruitment, atopic status, virus prevalence or 65 
exacerbation severity (Table E1). Given that the age of the patients ranged from 0.6-66 
12.3 years and the frequencies of some cell subsets (such as B cells and CD4+ T 67 
effector cells) change with increasing age (6), we used multiple regression to adjust 68 
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for age in our analyses. To account for varying effect size for common and rare cell 69 
subsets, we also normalised each subset to the median. We observed that elevated 70 
proportions of CD123+/CD11clo/HLA- basophils (as per Figure E1A) were positively 71 
associated with a history of >4 exacerbations, whereas high proportions of 72 
CD3+/CD4+/CD25+/FoxP3- T effector cells were negatively associated with >4 73 
exacerbations (Fig 1C). Within the basophil subset, we further observed that CD25 74 
expression was decreased in patients with >4 previous exacerbations (data not shown). 75 
The identified associations were also confirmed using the number of previous 76 
exacerbations as a continuous variable, basophils (p=0.02) and CD4+ T effector cells 77 
(p=0.04). 78 
 79 
After establishing that a history of >4 exacerbations was associated with altered 80 
proportions of basophils and CD4+ T effector cells during an acute exacerbation, we 81 
stratified the patients into two groups based on a median split of these cell types and 82 
assessed the risk of a future exacerbation within the follow-up period. By plotting 83 
exacerbation free time, we observed that patients with high basophil levels were more 84 
likely to experience a subsequent exacerbation (Fig 2A), whereas no difference was 85 
observed for patients with CD4+ T effector cell levels above or below the median (p = 86 
0.13), (data not shown) suggesting that not all changes associated with a history of 87 
exacerbations contribute to a recurrent disease phenotype. To confirm our findings, 88 
we studied an independent set of patients, and stratified them into two groups based 89 
on a median split of basophil levels during an asthma exacerbation. Of note, this 90 
group of patients were slightly older, had a higher prevalence of atopy, but had less 91 
severe exacerbations (Table E2). We again observed that patients with high basophil 92 
levels were more likely to experience an additional exacerbation within the follow-up 93 
period, compared to patients with low basophil levels (Fig 2B). Since patients with a 94 
history of >4 exacerbations were more likely to experience an additional exacerbation 95 
(p<0.001, data not shown), we investigated patients from our study population who 96 
had been sampled at their first ever exacerbation (n = 19). Of the patients with 97 
basophil levels above the median level for the study population (0.18% of PBMC), 7 98 
(70%) patients experienced a subsequent exacerbation within the follow-up period, 99 
whereas only 1 (11%) with basophils levels below the median had an additional 100 
exacerbation (χ2 p < 0.01) and Fig 2C. 101 
 102 
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These results suggest that patients with a high proportion of basophils within the 103 
PBMC preparation (i.e. patients with many basophils with a density that is below 104 
1.077 g/mL), were more likely to experience another exacerbation during the follow-105 
up period. These findings were not mirrored/reflected in total PBMC or whole blood 106 
basophil numbers, with the latter determined from clinical measurements of 107 
differential cell counts (data not shown), indicating that the predictive effect is 108 
specific to the proportion of basophils with lower density. This is likely a direct 109 
consequence of recent degranulation or activation, and elevated levels of these cells in 110 
PBMC may be indicative of enhanced basophil activity in the exacerbation event in 111 
the exacerbation-prone subset. In healthy subjects, basophils in the PBMC fraction 112 
indeed display elevated expression levels of selected activation markers (Figure E2A-113 
B), however no difference in granularity / side scatter profile between activated and 114 
resting basophils were observed in whole blood (Figure E2C). Of note, in subjects 115 
with both whole blood and PBMC basophil data available (n = 16), the ratio of low 116 
density PBMC basophils:total blood basophils was higher in the exacerbation prone 117 
group, 12.2% ± 7.2% compared to 4.4 ± 5.7% (p = 0.04). Basophils are known to be a 118 
significant producer of Th2 cytokines and are involved in defence against parasites 119 
(7). Moreover, they traffic to the airways during allergen challenge (8) and contribute 120 
to disease pathology in eosinophilic asthma (9). Our findings suggest that the 121 
proportion of de-granulated basophils may also be associated with recurrent 122 
exacerbations. These results will need to be confirmed using a larger cohort and 123 
particularly in patients experiencing their first ever exacerbation. Given that early 124 
identification of patients with recurrent asthma exacerbations is difficult, the use of 125 
basophil proportion and density as a potential marker warrants further exploration. 126 
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FIGURE LEGENDS  171 
Figure 1 172 
A-B Patient exacerbation history at the time of sampling plotted against age (A) or 173 
per patient distribution (B). Shaded area indicates patients with >4 exacerbations. C 174 
Normalised proportions of cellular subsets comparing children with a history of >4 or 175 
≤4 exacerbations, adjusted for age. * p<0.05, n = 40.  176 
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 177 
Figure 2 178 
A-B Exacerbation free time after recruitment and sampling is plotted for all patients 179 
comparing the proportion of basophils either above or below median levels in the 180 
original cohort (A) as well as an independent patient set (B). C Exacerbation free time 181 
in the combined patient cohort following recruitment and sampling, comparing patient 182 
basophil levels either above or below combined median levels. Significance of 183 
difference was calculated using log-rank test. 184 
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Table E1 – Patient demographics at an acute exacerbation in patients with more than 4 and 4 
or less previous exacerbations. For assessments of statistical significance between groups, 
Pearson’s χ2 or one-way ANOVA were used for categorical or continuous variables, 
respectively, as appropriate. 
 ≤4 previous 
exacerbations 
>4 previous 
exacerbations 
Significance 
of 
difference 
(p) 
Number of patients, n (%) 29 (73%) 11 (28%) n/a 
Age, mean years (range) 4.9 (0.6-12) 5.9 (1.8-12.3) 0.35 
Male gender, n (%) 17 (58.6%) 7 (63.6%) 0.77 
Family history of asthma 
(parents or siblings), n (%) 
20 (83.3%) 11 (100%) 0.15 
Atopy to aeroallergen, n (%) 20 (69.0%) 6 (54.5%) 0.39 
Total IgE, mean IU/mL 
(range) 
334.3 (21.1-
1270.4) 
328.6 (24.4-
1938.0) 
0.97 
Season recruited   0.27 
Spring (Sept – Nov) 7 (24.1%) 3 (27.3%)  
Summer (Dec – Feb) 4 (13.8%) 0 (0%)  
Autumn (Mar – May) 10 (34.5%) 2 (18.2%)  
Winter (Jun – Aug) 8 (27.6%) 6 (54.6%)  
Admitted to hospital, n (%) 27 (93.1%) 10 (90.9%) 0.82 
Hours from last oral 
corticosteroid administration 
to blood collection, mean 
(range) 
7.6 (0.8-49.5) 11.8 (2-25.2) 0.23 
Exacerbation severity Z-
score, mean (range) 
-.07 ((-2.2)-1.6) -0.2 ((-1.4)-1.2) 0.68 
Total PBMC cell count, x 
105/mL mean (range) 
11.0 (4.4-21) 13.1 (5.4-28.2) 0.22 
Respiratory viral infection 
positive, n (%) 
21 (91.3%) 10 (90.1%) 0.97 
Diagnosis at sample   0.35 
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Acute asthma, n (%) 23 (79.3%) 8 (72.73%)  
Virus induced wheeze, n (%) 5 (17.2%) 2 (18.2%)  
Other, n (%) 1 (3.5%) 1 (9.1%)  
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Table E2 – Patient demographics of the two cohorts. For assessments of statistical 
significance between groups, Pearson’s χ2 or one-way ANOVA were used for categorical or 
continuous variables, respectively, as appropriate. 
 Original cohort Confirmation 
cohort 
Significance 
of 
difference 
(p) 
Number of patients, n 40 18 n/a 
Age, mean years (range) 5.1 (0.6-12.3) 9.3 (6.9-13.2) <0.001 
Male gender, n (%) 24 (60.0%) 11 (61.1%) 0.94 
Family history of asthma 
(parents or siblings), n (%) 
31 (88.6%) 13 (81.3%) 0.48 
Atopy to aeroallergen, n (%) 26 (65.0%) 18 (100%) 0.004 
Total IgE, mean IU/mL 
(range) 
333.0 (21.1-
1938.0) 
618.1 (123.7-
1765.2) 
0.02 
Season recruited   0.94 
Spring (Sept – Nov) 10 (25%) 4 (22.2%)  
Summer (Dec – Feb) 4 (10%) 1 (5.6%)  
Autumn (Mar – May) 12 (30%) 6 (33.3%)  
Winter (Jun – Aug) 14 (35%) 7 (38.9%)  
Admitted, n (%) 37 (92.5%) 14 (87.5%) 0.55 
Hours from last oral 
corticosteroid administration 
to blood collection, mean 
(range) 
8.7 (.8-49.5) 5.3 (0.4-14.8) 0.21 
Exacerbation severity Z-score, 
mean (range) 
-0.1 ((-2.2)-1.6) -0.8 ((-2.2)-1.2 0.003 
Total PBMC cell count x 
105/mL, mean (range) 
11.6 (4.4-28.2) 10.6 (3.4-20.1) 0.46 
Respiratory viral infection 
positive, n (%) 
31 (91.2%) 10 (71.4%) 0.08 
Diagnosis at sample   0.19 
Acute asthma, n (%) 31 (77.5%) 18 (100%)  
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Virus induced wheeze, n (%) 7 (17.5%) 0  
Other, n (%) 2 (5%) 0  
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SUPPLEMENTARY DATA – Leffler et al. 
 
METHODS 
Patients and cell samples 
Two cohorts of patients (n=40 and n=18) with asthma exacerbations, were selected 
from the Perth based MAVRIC cohort, which was approved by the local ethics 
committee (Ethics approval# 1761EP). Patients were recruited when they presented to 
a tertiary children’s hospital with a lower respiratory illness in Perth, Western 
Australia. All respiratory visits to hospital from birth were determined for each child 
using the Western Australia public hospital database, which records all visits to a 
public hospital. Blood was collected within 24 hours of presentation to hospital and 
PBMCs were obtained using lymphoprep (Axis-Shield) and stored in liquid nitrogen. 
Atopy to an aeroallergen was defined as returning at least one of the following (i) 
positive skin-prick test (≥3 mm wheal diameter), (ii) specific-IgE against HDM, cat or 
mixed grasses ≥0.35 kU/L or (iii) history of allergic / anaphylactic reactions following 
exposure to an aeroallergen. Acute asthma severity scores were assigned to each child 
at recruitment using a modified National Institute of Health score with separate scales 
for children over or under 2 years of age as previously (1, 2). Separate severity Z 
scores were calculated for each child within each of the two age groups to provide 
standardized scores across the whole cohort. This standardised score was then used 
across all the subjects analysed. Viral prevalence was determine using a panel of 
common respiratory pathogens as well as genetic characterisation of respiratory viral 
infections as previously described (3). Patient characteristics are summarised in Table 
E2. Additionally, fresh blood from healthy volunteers was stimulated with 10 ng/ml 
PMA for 20 min at 37 °C prior to separation on lymphoprep as above and/or red 
blood cell lysis in 0.144 M NH4Cl and 1 mM NaHCO3 for 15 min. Granulocyte and 
PBMC fraction was analysed using flow cytometry as below. 
 
Flow cytometry  
Frozen PBMC were thawed at 37 °C, suspended in ice-cold RPMI supplemented with 
10% fetal calf serum, spun down and resuspended in RPMI. Viability, which in 
general was above 80% was assessed using trypan blue exclusion. One million cells 
were stained with CD19-FITC (#555412, BD), CD123-PE CF594 (#562391, BD), 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 2
HLA-DR PerCP (#347364, BD), CD11c PE-Cy7 (#561356, BD), FcεR1α APC (#17-
5899-42, eBioscience), CD14 APC-Cy7 (#641394, BD), CD4 V500 (#560768, BD), 
CD11b BV605 (#562723, BD), CD127 BV786 (#563324, BD), CD25 BV421 
(#562442, BD), CD3 AF700 (#561027, BD) for 20 min on ice followed by fixation 
and permeabilisation using FoxP3 staining kit (eBioscience) and stained using FoxP3 
PE (#560852, BD). For basophil specific analysis the following markers were used:  
CD19-FITC, CD123-PE CF594, HLA-DR PerCP, CD11c PE-Cy7, FcεR1α APC, 
CD14 APC-Cy7, CD63 V450 (#561984, BD) and CD203c BV510 (#563297, BD). 
Samples were acquired using a LSR-Fortessa (BD) and analysed using FlowJo 10.3 
(FlowJo LLC) and viSNE at Cytobank.org (Cytobank). 
 
Statistics 
The statistical difference between two patient groups was calculated using One-way 
ANOVA or Pearsons χ2 test depending on data characteristics. Age-adjusted 
associations were calculated using nominal logistic-regression analysis. Time to next 
exacerbation was plotted using Kaplan-Meier and statistical significance of difference 
between patient groups was calculated using the Log-Rank test. All statistical analysis 
was performed using JMP 13 (SAS, NSW, Australia) and data was visualised using 
Prism 7.0a (GraphPad, CA, USA). 
 
FIGURE LEGENDS 
Figure E1 A-B Gating strategy to identify relevant PBMC cell subset. Cell 
population data used in this study was derived using manual gating (A). Gating was 
confirmed using t-distributed stochastic neighbour embedding (t-SNE)-based 
algorithm which is used to reduce multi-dimensional flow cytometry data into two 
dimensions (B). 
 
Figure E2 A-B Surface expression of CD63 (A) and CD203c (B) on 
CD123+/CD11clo/HLA- basophils in granulocyte and PBMC fractions following 
control or PMA stimulated fresh blood. C Mean side scatter (SSC) of total basophils 
in whole blood following control or PMA stimulated samples. Statistically significant 
difference between cell fractions is indicates as *: p<0.05 or between control or PMA-
stimulated samples within cell fraction as #: p<0.05 and ##: p<0.01, n.s: not 
significant. 
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